Market Research Logo

Global mAb Biosimilars Market 2016-2020

Global mAb Biosimilars Market 2016-2020

About Biosimilars

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

Technavio’s analysts forecast the spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography:

  • Europe
  • Asia
  • ROW
Technavio's report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Hospira
Other prominent vendors
  • 3SBio
  • Accord Healthcare
  • AET Biotech
  • Allergan
  • Alvartis Pharma
  • Amega Biotech
  • Amgen
  • Apotex
  • Aspen
  • AstraZeneca
  • Aurobindo Pharma
  • Baxter
  • Bharat Serums
  • Bio Sidus
  • Biogen
  • Bionovis
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Boston Oncology
  • Cipla
  • Coherus Biosciences
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • Gedeon Richter
  • GeneScience Pharmaceuticals
  • GSK
  • Hetero Drugs
  • iBio
  • Intas Pharmaceuticals
  • JCR Pharmaceuticals
  • LG Lifesciences
  • Lonza
  • Merck
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Novartis
  • Pfenex
  • Pfizer
  • Ranbaxy Laboratories
  • Roche Holding
  • Samsung Biologics
  • Sanofi
  • Synthon
Market driver
  • Rise in number of patent expiries
  • For a full, detailed list, view our report
Market challenge
  • Physicians' reluctance to prescribe biosimilars
  • For a full, detailed list, view our report
Market trend
  • Emergence of biosimilars
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Monoclonal Antibody (mAb) Biosimilars Market: Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Natco Pharma, Novartis, Pfenex, Pfizer, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, and Synthon.

Commenting on the report, an analyst from Technavio’s team said: “One trend spurring growth is the emergence of biosimilars. At present, it has been observed that due to the increase in geriatric population, the prevalence of chronic diseases, such as rheumatoid arthritis, psoriatic arthritis, cancers, and metabolic disorders, has increased. As a result, Biosimilars will play a major role in this scenario. The increased sales of biosimilars are expected to pull down the sales of biologics during the forecast period.”

According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries. A biosimilar can be developed only after the patent expiry of the original product . Many first-generation biopharmaceuticals have expired or will expire during the forecast period. For instance, the patent of drugs such as Rituxan/MabThera, Remicade, Herceptin, Humira, Avastin, Synagis, Erbitux, and Lucentis are expected to expire during the forecast period.

Further, the report states that a major challenge for this market is the physicians' reluctance to prescribe biosimilars. Physicians are reluctant to prescribe biosimilars to patients, as mAbs cannot be substituted with these drugs. mAbs are developed using a living system or a genetically modified organism. Any minute variation in the entire process will have adverse effects on the safety and effectiveness of the final product. Biosimilars can also not be used during post-marketing surveillance as the substitution of drugs is prohibited during this period.

Companies Mentioned

Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Natco Pharma, Novartis, Pfenex, Pfizer, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, and Synthon.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
    • Assumptions
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Global mAb biosimilars market: Snapshot
      • Table Global mAb biosimilars market: Growth analysis
      • Table Global mAb biosimilars market: Key buying criteria 2015
      • Table Global mAb biosimilars market: Timeline 2014-2020
      • Table Global mAb biosimilars market: Impact of key customer segments 2015
    • Biosimilars: Overview
      • Table Definition of biosimilars by agencies
    • Comparative analysis of generic small molecules and biosimilars
      • Table Comparison between generic small molecules and biosimilars
      • Table Impact of biosimilars cost savings on different sectors
      • Table Factors affecting success of biosimilars
      • Table Biosimilars industry: Point-of-view
      • Table Factors influencing uptake of biosimilars
    • Biosimilars market opportunities
      • Table Global mAb biosimilars market: Strategic factors for new market entrants
    • Challenges for new entrants
      • Table Challenges for new entrants
    • Bio-betters
      • Table Bio-betters and its impact on market
  • Pipeline portfolio
    • Table Global mAb biosimilars market: Pipeline snapshot 2015
    • Table Pipeline portfolio: Global mAb biosimilars market 2015
  • Market landscape
    • Market overview
      • Table Patent expiry in key mAb biosimilars markets 2000-2020
      • Table Global mAb biosimilars market: Developed and emerging markets 2015
      • Table Global mAb biosimilars market 2015-2020 ($ millions)
      • Table Biosimilars: Savings potential in five European countries and US ($ billions) 2016-2020
      • Table Global spending on mAb biosimilars 2010-2020 ($ billions)
      • Table Global mAb biosimilars market: Key metrics analysis snapshot
      • Table Current and future trends in global mAb biosimilars market
      • Table Factors influencing the global mAb biosimilars market 2015
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by application
    • Table Global mAb biosimilars market: Segmentation by application (2015-2020)
    • Table Applications of mAb biosimilars and its impact on growth of market
    • Table Global mAb biosimilars market segmentation: Growth cycle analysis
    • Global chronic and autoimmune diseases mAb biosimilars market
      • Table Population aged 60 years and over (millions)
      • Table Global chronic and autoimmune diseases mAb biosimilars market 2015-2020 ($ millions)
      • Table Opportunity analysis of chronic and autoimmune diseases mAb biosimilars market by application
    • Global oncology mAb biosimilars market
      • Table Global incidence of cancer 2015-2020 (millions)
      • Table Global oncology mAb biosimilars market 2015-2020 ($ millions)
      • Table Opportunity analysis of global oncology mAb biosimilars market by type of application
      • Table Global mAb biosimilars market segmentation by application 2015
  • Geographical segmentation
    • Global mAb biosimilars market by geographical segmentation 2015-2020
      • Table Global mAb biosimilars market by geography: Outlook 2015-2020
      • Table Global mAb biosimilars market by geography 2015
      • Table Market penetration of originators and biosimilars by region/country
      • Table Global mAb biosimilars market landscape: Country analysis
    • mAb biosimilars market in Europe
      • Table mAb biosimilars market in Europe: Opportunity analysis
      • Table mAb biosimilars market in Europe 2015-2020 ($ millions)
      • Table PEST analysis: mAb biosimilars market in Europe 2015
    • mAb biosimilars market in Asia
      • Table mAb biosimilars market in Asia: Opportunity analysis
      • Table mAb biosimilars market in Asia 2015-2020 ($ millions)
      • Table PEST analysis: mAb biosimilars market in Asia 2015
    • mAb biosimilars market in rest of the world
      • Table mAb biosimilars market in rest of the world: Opportunity analysis
      • Table mAb biosimilars market in rest of the world 2015-2020 ($ millions)
      • Table Benefits of mAb biosimilars to US healthcare system
      • Table PEST analysis: mAb biosimilars market in rest of the world 2015
  • Market drivers
    • Table Impact of drivers and challenges on global mAb biosimilars market
    • Rise in number of patent expiries
      • Table Patent analysis of mAb in the US
      • Table Patent analysis of biologicals in Europe
    • Need for cost-effective treatment
    • Reimbursement benefits for biosimilars
    • Favorable government regulations
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Physicians' reluctance to prescribe biosimilars
      • Table Physicians' reluctance to prescribe biosimilars: Key reasons
    • Multiple manufacturing complexities
    • Risks related to drug failure
    • Limited availability of biosimilar products
    • Difficulties in patient recruitment for clinical trials
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Global mAb biosimilars market: Impact assessment of key trends
    • Emergence of biosimilars
    • Outsourcing of manufacturing activities
    • Need for high investment in R&D
    • High growth in the emerging markets
    • Rising number of strategic collaborations
  • Vendor landscape
    • Competitive scenario
      • Table Competitive assessment of vendors
      • Table Key vendors: Geographical presence 2015
      • Table Major vendors in global mAb biosimilars market: Mergers, acquisitions, and partnerships
  • Key vendor analysis
    • Biocon
      • Table Biocon profile
      • Table Biocon: Metrics analysis
      • Table Biocon growth strategy matrix
      • Table Biocon: Opportunity assessment
    • Celltrion
      • Table Celltrion profile
      • Table Celltrion: Metrics analysis
      • Table Celltrion growth strategy matrix
      • Table Celltrion: opportunity assessment
    • Dr. Reddy's Laboratories
      • Table Dr. Reddy's Laboratories profile
      • Table Dr. Reddy's Laboratories: Metrics analysis
      • Table Dr. Reddy's Laboratories growth strategy matrix
      • Table Dr. Reddy's Laboratories Opportunity assessment
    • Hospira
      • Table Hospira profile
      • Table Hospira: Metrics analysis
      • Table Hospira growth strategy matrix
      • Table Hospira opportunity growth assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report